THIOPENTONE INFUSION IN ICU- THERE IS MORE TO THIS THAN MEETS THE EYE

doi:10.1136/archdischild-2012-302724.0962

G Subramanian, O Mok, J Brierley. PICU, Great Ormond Street Hospital, London, UK

Thiopentone infusion is used to manage patients with Traumatic Brain Injury with persistent raised Intracranial pressure (ICP) and in treating intractable seizures. Pupillary abnormalities (unequal or fixed and dilated) can occur as a complication. The aim of this study was to determine factors associated with this complication.

Methods Retrospective review of patients admitted to a tertiary level PICU between 2000–2011 receiving thiopentone infusion or >2 boluses (not as part of Rapid sequence intubation). 59 patients were identified. Patients who had dilating eye drops were excluded. Quantitative variables are expressed as mean and Standard deviation, qualitative variables as percentages. Student’s t-test is used for comparison of quantitative variables.

Results The mean age of study population was 6.5 years (±5.3). Thiopentone was used for ICP management in 44 (74.6%) and sepsis in 15 (25.4%). 13 (22%) episodes of pupillary abnormality (of which 8 had fixed and dilated pupils) were recorded in 12 (20.3%) patients. Dose/kg (p=0.675), maximum rate of infusion (p=0.57) or duration of infusion (p=0.51) were not significantly correlated to the occurrence of this complication. Age >9 years was significantly associated (p=0.05) with abnormal pupillary reaction.

Conclusion High dose, maximum infusion rate or longer duration of thiopentone infusion was not associated with abnormal pupillary reaction. Drug levels were not done in all and it is not known whether this complication is a result of genotypic variation in drug metabolism. It is however important to have continuous EEG monitoring to ensure that the optimal dose is administered to the patient.

Abstracts

PRENATAL PREGNANCY-ASSOCIATED PLASMA PROTEIN A LEVELS AND NEONATAL COMPLICATIONS IN POST-TERM PREGNANCIES

doi:10.1136/archdischild-2012-302724.0963

1AR Zizzo, 4K Kirkgarda, 1TB Henriksen, 1N Uldbjerg. 1Department of Obstetrics and Gynecology, 2Department of Pediatrics, Aarhus University Hospital, Skejby, Aarhus, Denmark

Objectives To assess the association between serum pregnancy-associated plasma protein A (PAPP-A) measured in the first trimester and perinatal complications in post-term pregnancies.

Methods A total of 4948 singleton pregnant women, who delivered after 40 gestational weeks, were included at Aarhus University Hospital between January 2005 and December 2007. Serum levels of PAPP-A were determined at the first-trimester screening for Down syndrome (GA 80 – 13+6). Labor was not induced routinely until 42+2 weeks of gestation. However, in women with diabetes mellitus, gestational diabetes, preeclampsia, hypertension, prelab rupture of membranes, twin pregnancies, fetal growth restriction and intrahepatic cholestasis, labor were induced by 40 completed weeks or earlier and were not included in the study.

Results In post-term pregnancies first-trimester serum PAPP-A below 0.4 MoM was associated with small weight for gestation (< 5th centile)(ORr 1.7, 95% CI 0.9–3.0), Appar score of less than 7 at 5 minutes (ORr 5.4, 95% CI 2.0–14.3), admission to the neonatal intensive care unit (ORr 1.5, 95% CI 1.0–2.3), and newborn hypoglycemia (ORr 3.4, 95% CI 1.8–6.4). In neonates with small weight for gestation the risk of hypoglycemia was increased considerably (OR 14.6, 95% CI 5.4–58.0).

Conclusions Low first trimester serum PAPP-A was associated with increased neonatal morbidity in post-term pregnancies, particularly in newborns with low birth weight. Thus, PAPP-A may qualify the timing of induction of labor in these pregnancies and low PAPP-A may indicate more closely follow-up when past 40 weeks of gestation.

IS THE PLACEBO EFFECT REVEALABLE IN NEWBORNS? RESULTS FROM AN RCT IN OSTEOPATHY

doi:10.1136/archdischild-2012-302724.0964

1F Cerritelli, G Barbafante, C Renzetti, F Ficchi, N Logreto, G Pizzolorusso, F Fusilli, C D’Incecco. 1European Institute for Evidence Based Osteopathic Medicine; 2Accademia Italiana Osteopatia Tradizionale; 3Neonatal Intensive Care Unit, Pescara Hospital, Pescara, Italy

Background and Aims Placebo effect has been largely studied and debated in medicine. Interestly the majority of studies focused on children and adults but not on newborns. In the field of osteopathic medicine, few studies documented this effect using sham therapy. A previous study showed the association between OMT and LOS. In the field of osteopathic medicine, few studies documented this effect using sham therapy. A previous study showed the association between OMT and LOS. In the field of osteopathic medicine, few studies documented this effect using sham therapy. A previous study showed the association between OMT and LOS. In the field of osteopathic medicine, few studies documented this effect using sham therapy. A previous study showed the association between OMT and LOS.

Methods A double blinded randomized control trial was carried out on 250 preterm newborns, GA >29 and <37 weeks and free of medical complications. After enrollment, all subjects were randomly assigned to study (N=107) and control group (N=143). All preterms received routine pediatric care and osteopathic sham therapy was administered to the study group only for the entire period of hospitalization. Primary outcome was to evaluate the effectiveness of sham therapy in reducing LOS.

Results At entry, univariate statistical analysis showed no differences between groups. At the end of the study, after adjusting for all potential confounders, generalized linear model analysis showed no difference on the primary outcome (mean difference between study and control group: 2.444; 95%CI –0.447, 5.337; p=0.09).